Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (19 quarters reported)
$129M in Q4 2021 → $164M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| PP Praxis Precision Medicines I | 18.1% | Trimmed 12% | 88,781 | $29.7M |
| Maplight Therapeutics Inc | 10.8% | Unchanged | 492,893 | $17.7M |
| Sutro Biopharma Inc | 10.4% | Unchanged | 512,160 | $17M |
| Immix Biopharma Inc | 6.8% | Added 47% | 1,085,000 | $11.2M |
| Protara Therapeutics Inc | 6.6% | Added 0.4% | 2,844,652 | $10.9M |
| Abivax Sa | 5.3% | Trimmed 15% | 65,630 | $8.75M |
| Tenax Therapeutics Inc | 4.9% | Trimmed 5.7% | 549,985 | $8M |
| Anteris Technologies Global | 4.2% | Unchanged | 700,000 | $6.9M |
| Edesa Biotech Inc | 4.1% | Unchanged | 827,500 | $6.73M |
| Evommune Inc | 3.7% | Added 1.1% | 451,255 | $6M |
| Avalo Therapeutics Inc | 3.7% | Added 75% | 324,452 | $6M |
| Xencor Inc | 2.5% | Added 2.0% | 255,000 | $4.11M |
| Rezolute Inc | 2.4% | Unchanged | 750,000 | $3.9M |
| Heron Therapeutics Inc | 2.3% | Unchanged | 8,753,290 | $3.74M |
| Verrica Pharmaceuticals Inc | 1.8% | Unchanged | 471,559 | $2.89M |
| C4 Therapeutics Inc | 1.6% | New | 570,000 | $2.66M |
| Eupraxia Pharmaceuticals Inc | 1.4% | Unchanged | 352,000 | $2.33M |
| Adma Biologics Inc | 1.3% | New | 250,000 | $2.09M |
| Rein Therapeutics Inc | 1.1% | New | 1,700,000 | $1.77M |
| Lyell Immunopharma Inc | 0.9% | Added 2.9% | 105,000 | $1.48M |
| Nasus Pharma Ltd | 0.8% | Unchanged | 359,390 | $1.26M |
| PM Profound Med Corp | 0.7% | Trimmed 40% | 170,278 | $1.13M |
| Jasper Therapeutics Inc | 0.7% | Unchanged | 2,668,395 | $1.12M |
| Tenax Therapeutics Inc Call | 0.6% | New | 68,700 | $1M |
| Protagonist Therapeutics Inc | 0.3% | Unchanged | 3,700 | $454K |
| Cytomx Therapeutics Inc. | 0.3% | Trimmed 78% | 120,000 | $450K |
| Neumora Therapeutics Inc. | 0.2% | Added 188% | 230,000 | $391K |
| Nurix Therapeutics Inc | 0.2% | Unchanged | 16,000 | $388K |
| Ovid Therapeutics Inc | 0.2% | Trimmed 19% | 130,000 | $350K |
| Precision Biosciences Inc | 0.2% | Unchanged | 40,000 | $314K |
| Mineralys Therapeutics Inc | 0.2% | Unchanged | 11,000 | $297K |
| Macrogenics Inc | 0.2% | Added 100% | 60,000 | $277K |
| CP Corbus Pharmaceuticals Hldgs | 0.1% | Unchanged | 26,000 | $244K |
| Artiva Biotherapeutics Inc | 0.1% | Unchanged | 25,000 | $243K |
| Replimune Group Inc | 0.1% | Unchanged | 20,000 | $221K |
| Syndax Pharmaceuticals Inc | 0.1% | Unchanged | 10,000 | $219K |
| Immunome Inc | 0.1% | Unchanged | 10,000 | $212K |
| Tectonic Therapeutic Inc | 0.1% | New | 6,000 | $206K |
| Rocket Pharmaceuticals Inc | 0.1% | Trimmed 80% | 60,000 | $205K |
| Karyopharm Therapeutics Inc | 0.1% | Added 33% | 20,000 | $195K |
| An2 Therapeutics Inc | 0.1% | New | 40,000 | $194K |
| Viridian Therapeutics Inc | 0.1% | Trimmed 89% | 10,000 | $184K |
| Scynexis Inc | 0.1% | New | 40,000 | $163K |
| Quoin Pharmaceuticals Ltd | 0.1% | Trimmed 62% | 32,372 | $157K |
| Xilio Therapeutics Inc | 0.1% | Unchanged | 14,285 | $137K |
| Inspiremd Inc | 0.1% | Trimmed 93% | 148,138 | $104K |
| Kalaris Therapeutics Inc | 0.1% | Added 39% | 25,000 | $102K |
| Larimar Therapeutics Inc | 0.1% | Unchanged | 33,000 | $101K |
| PT Proqr Thrapeutics N V | 0.1% | Unchanged | 45,000 | $83.7K |
| Context Therapeutics Inc | 0.0% | Trimmed 40% | 59,700 | $33.1K |
| Gossamer Bio Inc | 0.0% | Unchanged | 70,000 | $11.5K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| ET Esperion Therapeutics Inc Ne | Exited | −1,720,000 | −$4.71M | — |
| PP Praxis Precision Medicines I | Trimmed | −12,000 | −$4.02M | 18.1% |
| Immix Biopharma Inc | Added | +345,000 | +$3.56M | 6.8% |
| C4 Therapeutics Inc | New | +570,000 | +$2.66M | 1.6% |
| Avalo Therapeutics Inc | Added | +139,330 | +$2.57M | 3.7% |
| Adma Biologics Inc | New | +250,000 | +$2.09M | 1.3% |
| Rein Therapeutics Inc | New | +1,700,000 | +$1.77M | 1.1% |
| Cytomx Therapeutics Inc. | Trimmed | −420,000 | −$1.58M | 0.3% |
| Abivax Sa | Trimmed | −11,370 | −$1.52M | 5.3% |
| Viridian Therapeutics Inc | Trimmed | −81,123 | −$1.49M | 0.1% |
Showing the 10 largest of 33 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cidara Therapeutics Inc | Exited | −108,404 | −$23.9M | — |
| Tenax Therapeutics Inc | Added | +500,000 | +$8M | 5.8% |
| Immix Biopharma Inc | Added | +705,000 | +$6.42M | 4.2% |
| Sutro Biopharma Inc | Added | +200,160 | +$4.99M | 8.0% |
| LH Lantheus Hldgs Inc | Exited | −74,687 | −$4.97M | — |
| Anteris Technologies Global | New | +700,000 | +$3.89M | 2.4% |
| Mineralys Therapeutics Inc | Trimmed | −140,000 | −$3.79M | 0.2% |
| Rapt Therapeutics Inc | Exited | −108,000 | −$3.66M | — |
| Xencor Inc | New | +250,000 | +$3.02M | 1.9% |
| Terns Pharmaceuticals Inc | Exited | −70,000 | −$2.83M | — |
Showing the 10 largest of 40 changes.
quarter ended December 31, 2025 · filed February 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| PP Praxis Precision Medicines I | Trimmed | −32,024 | −$9.44M | 17.2% |
| Maplight Therapeutics Inc | New | +522,305 | +$9.17M | 5.3% |
| Evommune Inc | New | +506,754 | +$8.68M | 5.0% |
| ET Esperion Therapeutics Inc Ne | New | +1,210,000 | +$4.48M | 2.6% |
| ZP Zooz Pwr Ltd | Exited | −2,000,000 | −$4.28M | — |
| Verrica Pharmaceuticals Inc | New | +471,559 | +$3.92M | 2.3% |
| Alumis Inc | Exited | −946,683 | −$3.78M | — |
| Protara Therapeutics Inc | Added | +695,652 | +$3.71M | 8.8% |
| Sutro Biopharma Inc | New | +312,000 | +$3.61M | 2.1% |
| Sutro Biopharma Inc | Exited | −3,120,000 | −$2.71M | — |
Showing the 10 largest of 31 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Tourmaline Bio Inc | Trimmed | −388,089 | −$18.6M | 0.3% |
| V Veronapharmaplc | Exited | −95,000 | −$8.99M | — |
| Z Zevratherapeuticsinc | Exited | −715,000 | −$6.3M | — |
| Abivax Sa | New | +64,389 | +$5.47M | 5.1% |
| ZP Zooz Pwr Ltd | New | +2,000,000 | +$4.28M | 4.0% |
| LH Lantheus Hldgs Inc | New | +73,545 | +$3.77M | 3.5% |
| A Arvinasinc | Exited | −500,000 | −$3.68M | — |
| S Scpharmaceuticalsinc | Exited | −917,668 | −$3.5M | — |
| Inspiremd Inc | Added | +1,239,669 | +$2.99M | 4.9% |
| L Liquidiacorporation | Exited | −239,260 | −$2.98M | — |
Showing the 10 largest of 42 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Acelyrin Inc | Exited | −3,366,945 | −$8.32M | — |
| Springworks Therapeutics Inc | Exited | −185,520 | −$8.19M | — |
| C Cidaratherapeuticsinc | New | +100,000 | +$4.87M | 4.8% |
| A Alumisinc | New | +1,620,846 | +$4.86M | 4.8% |
| A Arvinasinc | New | +500,000 | +$3.68M | 3.6% |
| R Rezoluteinc | Added | +350,000 | +$1.56M | 3.3% |
| P Praxisprecisionmedicinesi | Trimmed | −35,666 | −$1.5M | 6.2% |
| S Sutrobiopharmainc | Added | +2,030,000 | +$1.45M | 2.2% |
| P Protaratherapeuticsinc | Added | +471,200 | +$1.43M | 6.4% |
| N Nektartherapeutics | New | +50,000 | +$1.29M | 1.3% |
Showing the 10 largest of 38 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Acelyrin Inc | New | +3,366,945 | +$8.32M | 8.6% |
| PP Praxis Precision Medicines I | Trimmed | −115,000 | −$4.36M | 7.2% |
| Verona Pharma PLC | Added | +45,000 | +$2.86M | 6.2% |
| Zevra Therapeutics Inc | Added | +365,000 | +$2.73M | 5.1% |
| Scpharmaceuticals Inc | New | +917,668 | +$2.41M | 2.5% |
| Mineralys Therapeutics Inc | New | +150,600 | +$2.39M | 2.5% |
| Nurix Therapeutics Inc | Exited | −97,889 | −$1.84M | — |
| Edesa Biotech Inc | New | +687,500 | +$1.68M | 1.7% |
| Kura Oncology Inc | Exited | −150,000 | −$1.31M | — |
| Instil Bio Inc | New | +69,000 | +$1.2M | 1.2% |
Showing the 10 largest of 37 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR Ser Tr | Exited | −150,000 | −$14.8M | — |
| Springworks Therapeutics Inc | New | +185,520 | +$6.7M | 5.8% |
| Protara Therapeutics Inc | Added | +1,005,000 | +$5.31M | 7.2% |
| PP Praxis Precision Medicines I | Trimmed | −50,666 | −$3.9M | 19.9% |
| Scpharmaceuticals Inc | Exited | −517,668 | −$2.36M | — |
| Verona Pharma PLC | New | +50,000 | +$2.32M | 2.0% |
| Replimune Group Inc | New | +181,367 | +$2.2M | 1.9% |
| Tela Bio Inc | Exited | −747,410 | −$1.89M | — |
| Tourmaline Bio Inc | Added | +92,605 | +$1.88M | 7.4% |
| Nurix Therapeutics Inc | New | +97,889 | +$1.84M | 1.6% |
Showing the 10 largest of 43 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Alimera Sciences Inc | Exited | −13,608,533 | −$75.7M | — |
| SS SPDR Ser Tr | New | +150,000 | +$14.8M | 13.9% |
| Liquidia Corporation | New | +300,000 | +$3M | 2.8% |
| Scpharmaceuticals Inc | New | +517,668 | +$2.36M | 2.2% |
| Outlook Therapeutics Inc | Exited | −247,084 | −$1.82M | — |
| Elevation Oncology Inc | Exited | −597,299 | −$1.61M | — |
| Zevra Therapeutics Inc | New | +200,000 | +$1.39M | 1.3% |
| CP Corbus Pharmaceuticals Hldgs | New | +50,000 | +$1.03M | 1.0% |
| Skye Bioscience Inc | Trimmed | −211,071 | −$825K | 0.8% |
| Jasper Therapeutics Inc | Trimmed | −38,076 | −$716K | 25.2% |
Showing the 10 largest of 17 changes.
Loading...
